|
|
| Antalgiques > Etude de marché sectorielle |
| Commercial Insight: Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities |
|
|
|
|
€ 12 160,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Juillet 2006 |
Taille du document : |
131 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (2) |
|
|
|
| 22 pages | Anglais
|
|
|
| Main
focus: |
clinical trials,sclerosis,rheumatoid arthritis,...,...
|
| Research
focus: |
market size and estimates,market outlook, |
| Geographic
focus: |
usa |
| |
|
|
|
|
| 27 pages | Novembre 2006 | Anglais
|
|
|
| Main
focus: |
clinical trials,clinical trial,toxicology,...,...
|
| Research
focus: |
market size and estimates,market segmentation, |
| Geographic
focus: |
usa,united kingdom,japan,australia,peru |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
US State Market Index: Anesthetics, in bulk form
12 pages | Juillet 2006 |
The metrics in this report cover three year trends in Anesthetics, in bulk form [Manufacturing sector], broken out on a state-by-state basis.
Analysis is based on data applied from 11 industry firm |
475,00 €
|
| |
| |
OTC Analgesics in France
10 pages | Juin 2005 |
Euromonitor International’s ‘OTC Analgesics in France' Major Market Profile report offers an introduction to the market.
It is c.
10 pages long and provides a top line overview of sales trends |
198,00 €
|
| |
| |
US Analgesics 2004
14 pages | Juillet 2004 |
Snapdata's US Analgesics 2004 report provides 2003 year-end market data, with 2004 estimates and five-year forecasts.
The report gives an instant overview of the US analgesic market, and covers non |
240,00 €
|
| |
| |
Commercial Insight: Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities
131 pages | Juillet 2006 |
IntroductionNeurontin (gabapentin) has finally been knocked off the top spot as a result of fierce generic incursion.
However, Pfizer's follow-on Lyrica (pregabalin), Lilly's Cymbalta (duloxetine) |
12 160,00 €
|
| |
| |
US State Market Index: Analgesics
12 pages | Juillet 2006 |
The metrics in this report cover three year trends in Analgesics [Manufacturing sector], broken out on a state-by-state basis.
Analysis is based on data applied from 7 industry firms.
Industry m |
475,00 €
|
| |
| |
The Pain Market Outlook to 2011
206 pages | Juin 2006 |
The patient populations for neuropathic and nociceptive pain are large, and are driven by separate disease trends that necessitate pain relief; across the seven major markets in 2005 it was estimated |
2 300,00 €
|
| |
| |
Anesthesia Competitors
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Pain Management
459 pages | Janvier 2006 |
This report analyzes the worldwide markets for Pain Management in Millions of US$.
The specific product segments analyzed are Pain Management Pharmaceuticals, Pain Management Devices, and Pain Mana |
3 091,00 €
|
| |
| |
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail to Nail Neuropathic Pain
183 pages | Juillet 2005 |
IntroductionThe neuropathic pain market has traditionally been a poorly defined area, with widely varying drug classes prescribed.
With many drugs now in clinical trials for key neuropathic pain su |
9 120,00 €
|
| |
| |
Pain Management
202 pages | Octobre 2006 |
Pain Management |
55,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Commercial Insight: Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities |
|
|
Introduction
Neurontin (gabapentin) has finally been knocked off the top spot as a result of fierce generic incursion. However, Pfizer's follow-on Lyrica (pregabalin), Lilly's Cymbalta (duloxetine) and Endo/Elan's Lidoderm (lidocaine patch 5%) are re-establishing market growth and laying the groundwork for new entrants.
Scope
*Detailed analysis of key brands, with sales and volume forecasts to 2014 for the neuropathic pain indication alone
*Assessment of current and future opportunities and threats in the neuropathic pain market across the seven major pharmaceutical markets
*Consideration of key events that may affect revenues in each of the seven major pharmaceutical markets are applied and discussed
*Lifecycle management case studies show how previously successful strategies should be applied in today's market
Highlights
After a brief slump in 2005, the neuropathic pain market is forecast to grow to $5.5 billion by 2015, led by Lyrica and Cymbalta. Pfizer's commitment to neuropathic pain and Lilly's targeted approach are both effective strategies that can be utilized by all new entrants.
The presence of generic gabapentin has introduced strong cost competition in the market. Setting a competitive price point for a new product is vital as healthcare payers continue to push for lower drug prices and generic prescribing although innovation is rewarded with a premium price and a high level of reimbursement in most countries.
The current concerns surrounding the use of NSAIDs and opioids will be beneficial to neuropathic pain drug companies as physicians seek alternative analgesics for their patients. However, if they are to realize the full potential of the market, companies need to focus on expanding the patient potential by supporting physician education programs.
Reasons to Purchase
*Quantify the future size of the neuropathic pain market in each of the seven major markets
*Understand key product differentiating factors that provide commercial advantages over existing therapies
*Compare market penetration and brand positioning strategies to those successfully employed by Pfizer, Endo, and Eli Lilly
|
|
Commercial Insight: Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities
|
|
|
PPLSEN
|
|
|
|
|
